Article Text

PDF
Etidronate for vertebral osteoporosis after the menopause

Abstract

Osteoporosis is serious, common and potentially preventable. In hospitals it most frequently presents as fracture of the hip or forearm; hip fractures alone occur in about 40,000 people each year in England and Wales, with a mortality of 15% and in-patient costs of approximately £200 million.1 Vertebral fractures are even more common, causing deformity and pain, but reliable figures for morbidity and cost are not available. Didronel PMO (etidronate + calcium; Norwich Eaton) has recently been introduced for the ‘treatment of established vertebral osteoporosis’.

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.